- Home
- DMAC vs CLAR Comparison
DMAC vs CLAR Comparison
Compare DMAC & CLAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- CLAR
- Stock Information
- Founded
- DMAC 2000
- CLAR 1957
- Country
- DMAC United States
- CLAR United States
- Employees
- DMAC N/A
- CLAR N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- CLAR Recreational Games/Products/Toys
- Sector
- DMAC Health Care
- CLAR Consumer Discretionary
- Exchange
- DMAC Nasdaq
- CLAR Nasdaq
- Market Cap
- DMAC 158.1M
- CLAR 150.4M
- IPO Year
- DMAC N/A
- CLAR N/A
- Fundamental
- Price
- DMAC $4.11
- CLAR $3.18
- Analyst Decision
- DMAC Strong Buy
- CLAR Strong Buy
- Analyst Count
- DMAC 2
- CLAR 4
- Target Price
- DMAC $8.00
- CLAR $5.50
- AVG Volume (30 Days)
- DMAC 102.4K
- CLAR 161.6K
- Earning Date
- DMAC 05-13-2025
- CLAR 05-08-2025
- Dividend Yield
- DMAC N/A
- CLAR 3.13%
- EPS Growth
- DMAC N/A
- CLAR N/A
- EPS
- DMAC N/A
- CLAR N/A
- Revenue
- DMAC N/A
- CLAR $255,437,000.00
- Revenue This Year
- DMAC N/A
- CLAR N/A
- Revenue Next Year
- DMAC N/A
- CLAR $6.30
- P/E Ratio
- DMAC N/A
- CLAR N/A
- Revenue Growth
- DMAC N/A
- CLAR N/A
- 52 Week Low
- DMAC $2.14
- CLAR $3.02
- 52 Week High
- DMAC $6.82
- CLAR $7.13
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- CLAR 44.52
- Support Level
- DMAC $3.92
- CLAR $3.05
- Resistance Level
- DMAC $4.33
- CLAR $3.18
- Average True Range (ATR)
- DMAC 0.29
- CLAR 0.14
- MACD
- DMAC 0.02
- CLAR 0.01
- Stochastic Oscillator
- DMAC 56.79
- CLAR 31.37
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About CLAR Clarus Corporation
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.